# EDGAR Filing Document

**Accession Number:** 0001621227
**File Stem:** 0001104659-25-102828
**Filing Date:** 2025-10
**Character Count:** 3584
**Document Hash:** 07b393d11af297f758db35031adb5174
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-25-102828.hdr.sgml**: 20251028

**ACCESSION NUMBER**: 0001104659-25-102828

**CONFORMED SUBMISSION TYPE**: 25

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20251028

**DATE AS OF CHANGE**: 20251028

**EFFECTIVENESS DATE**: 20251028

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Adaptimmune Therapeutics PLC
- **CENTRAL INDEX KEY:** 0001621227
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** X0
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 25
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-37368
- **FILM NUMBER:** 251421389

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 60 JUBILEE AVENUE
- **STREET 2:** MILTON PARK
- **CITY:** ABINGDON, OXFORDSHIRE
- **PROVINCE COUNTRY:** X0
- **BUSINESS PHONE:** 44 1235 430000

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 60 JUBILEE AVENUE
- **STREET 2:** MILTON PARK
- **CITY:** ABINGDON, OXFORDSHIRE
- **PROVINCE COUNTRY:** X0

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Adaptimmune Ltd
- **DATE OF NAME CHANGE:** 20141001

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D. C. 20549**

**FORM 25**

**NOTIFICATION OF REMOVAL FROM LISTING AND/OR**

**REGISTRATION UNDER SECTION 12(b) OF THE**

**SECURITIES EXCHANGE ACT OF 1934.**

Commission File Number <u>001-37368</u>

---

| |
|:---|
| Adaptimmune Therapeutics plc<br> The Nasdaq Capital Market |
| (Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered) |
| 60 Jubilee Avenue, Milton Park |
| Abingdon, Oxfordshire OX14 4RX |
| United Kingdom<br> (44) 1235 430000 |
| (Address, including zip code, and telephone number, including area code, of Issuer's principal executive offices) |
| American Depositary Shares, each representing six ordinary shares, par value £0.001 per share |
| (Description of class of securities) |

---

Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:

◻ 17 CFR 240.12d2-2(a)(1)

◻ 17 CFR 240.12d2-2(a)(2)

◻ 17 CFR 240.12d2-2(a)(3)

◻ 17 CFR 240.12d2-2(a)(4)

◻ Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange.1

⌧ Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with the rules of the Exchange and the requirements of 17 CFR 240.12d2-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.

Pursuant to the requirements of the Securities Exchange Act of 1934, Adaptimmune Therapeutics plc certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.

---

| | | |
|:---|:---|:---|
| October 28, 2025 | By: /s/ Adrian Rawcliffe | Chief Executive Officer |
| Date | Name: Adrian Rawcliffe | Title |

---

SEC 1654<br> (03-06) Potential persons who are to respond to the collection of information contained in this Form are not required to respond unless the Form displays a currently valid OMB control number.

1 Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.